26 research outputs found
Chronic gvhd dictionary-eurograft cost action initiative consensus report
No full textChronic graft versus host disease (cGVHD) affects patients after allogeneic hematopoietic stem cell transplantation (alloHSCT). This orphan disease poses a challenge for clinicians and researchers. The purpose of the cGVHD Dictionary is to provide a standardized structure for cGVHD databases on an international level, reconciling differences in data retrieval and facilitate database merging. It is derived from several consensus meetings of the EUROGRAFT consortium (European Cooperation in Science and Technology-COST Action CA17138) followed by a consensus process involving European Society for Blood and Marrow Transplantation (EBMT), US GvHD consortium and Center for International Bone Marrow Transplant Registry (CIBMTR). Databases used for the dictionary were: the National Institutes of Health (NIH) database, the Center for International Blood and Marrow Transplant Research, Applying Biomarkers to Minimize Long Term Effects of Childhood/Adolescent Cancer Treatment - Pediatric Blood and Marrow Transplant Consortium database, EBMT registry, the German-Austrian-Swiss GvHD registry, Italian Blood and Marrow Transplantation Society registry and Regensburg-Göttingen-Newcastle HSCT dataset. A four-part cGVHD Dictionary was formed based on the databases, consensus, and evidence in the literature. The Dictionary is divided into: (1) Patient characteristics, (2) Transplant characteristics, (3) cGVHD characteristics and (4) patient-reported quality of life, symptom burden and functional indicators.sponsorship: The analysis was performed in the framework of the COST project CA17138 cGvHD Eurograft (www.gvhd.eu).DW work was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) -Projekt-ID 324392634 -TRR221, subproject B10. (COST project|CA17138, Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)|324392634 -TRR221)status: Publishe
Successful Treatment of Recurrent Gastrointestinal Bleeding Due to Small Intestine Angiodysplasia and Multiple Myeloma with Thalidomide: Two Birds with One Stone
No full text
Therapy Decisions in Patients Evaluated in Specialized Chronic Graft-Versus-Host (cGVHD) Clinics Using 2014 Consensus Criteria for Diagnosis and Response Assessment
No full textPractice patterns in chronic graft-versus-host disease patient management and patient reported outcome measures across the EBMT allogeneic transplantation network
No full textsponsorship: This Letter to the Editor is supported by the European Cooperation in Science & Technology under the COST Action 17138 (Integrated European Network on Chronic Graft Versus Host Disease: EUROGRAFT; https://www.gvhd.eu) initiated and chaired by AMD from Newcastle University, UK, and further coordinated as grant holder by MI from Oslo University Hospital Oslo, Norway. Open Access funding enabled and organized by Projekt DEAL. (European Cooperation in Science & Technology under the COST Action|17138, Projekt DEAL, Oslo University Hospital Oslo, Norway)status: Publishe
Treatment of Multiple Relapsing Non-Melanoma Skin Cancers in a Patient with Severe Hemophilia A
No full text Although non-melanoma skin cancers are the most predominant malignancies in the Caucasian population and hemophilia A is one of the most frequent hereditary bleeding disorders, medical literature data about the management of non-melanoma skin cancers in patients with hemophilia are surprisingly scarce. In this case report we describe the treatment of a patient with multiple recurrent non-melanoma skin cancers and severe hemophilia A. The management of such patients could be very challenging, with possible significant bleeding complications, and requires a multidisciplinary approach. </jats:p
Amniotic membrane transplantation—a new approach to crossing the HLA barriers in the treatment of refractory ocular graft-versus-host disease
No full textNational Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report
No full text: Positive results from recent clinical trials have significantly expanded current therapeutic options for patients with chronic graft-versus-host disease (GVHD). However, new insights into the associations between clinical characteristics of chronic GVHD, pathophysiologic mechanisms of disease, and the clinical and biological effects of novel therapeutic agents are required to allow for a more individualized approach to treatment. The current report is focused on setting research priorities and direction in the treatment of chronic GVHD. Detailed correlative scientific studies should be conducted in the context of clinical trials to evaluate associations between clinical outcomes and the biological effect of systemic therapeutics. For patients who require systemic therapy but not urgent initiation of glucocorticoids, clinical trials for initial systemic treatment of chronic GVHD should investigate novel agents as monotherapy without concurrently starting glucocorticoids, to avoid confounding biological, pathological, and clinical assessments. Clinical trials for treatment-refractory disease should specifically target patients with incomplete or suboptimal responses to most recent therapy who are early in their disease course. Close collaboration between academic medical centers, medical societies, and industry is needed to support an individualized, biology-based strategic approach to chronic GVHD therapy
Iron deficiency anemia: preconceptional, pregnancy and postpartum management – a call for action
No full textron deficiency (ID) and iron deficiency anemia (IDA) are very common in women during their reproductive life, but often these conditions remain unrecognized and left untreated.Heavy menstrual bleeding (HMB) and pregnancy are associated with ID/IDA, influencing health and the physical and social lives of these individuals. Cross discipline expertise has considered evidence presented here of the pathophysiological mechanisms, the symptoms, the diagnostic criteria and the therapeutic approaches to ID/IDA.A call for action for IDA before and during pregnancy and in the postpartum period is discussed in this review. The uterine disorders causing HMB (which include, but are not limited to uterine fibroids, adenomyosis, endometrial polyps) not only contribute to IDA, but also to infertility and pregnancy complications. It is thus important to reveal and correct ID/IDA. During pregnancy iron requirement increases, thus ID/IDA are common, and these conditions may have a negative impact on pregnancy outcome. Hence, it is critical to early identify and treat ID/IDA during pregnancy with iron replacement therapy. Postpartum IDA may occur following blood loss and major hemorrhage at delivery. In this respect, patient blood management is the best approach for alleviating this critical situation.Action to increase the awareness for women and physicians on the diagnosis and treatment of ID/IDA is essential to improve health outcomes for women across their life course and for their infants
